A detailed history of Two Seas Capital LP transactions in Immunovant, Inc. stock. As of the latest transaction made, Two Seas Capital LP holds 676,614 shares of IMVT stock, worth $18.6 Million. This represents 6.26% of its overall portfolio holdings.

Number of Shares
676,614
Previous 692,406 2.28%
Holding current value
$18.6 Million
Previous $18.3 Million 1.83%
% of portfolio
6.26%
Previous 7.31%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$27.51 - $27.51 $434,437 - $434,437
-15,792 Reduced 2.28%
676,614 $18.6 Million
Q2 2024

Aug 14, 2024

BUY
$25.1 - $31.61 $3.79 Million - $4.78 Million
151,111 Added 27.92%
692,406 $18.3 Million
Q1 2024

May 15, 2024

BUY
$30.27 - $43.79 $10.4 Million - $15 Million
342,543 Added 172.35%
541,295 $17.5 Million
Q4 2023

Feb 14, 2024

SELL
$31.31 - $44.19 $7.15 Million - $10.1 Million
-228,504 Reduced 53.48%
198,752 $8.37 Million
Q3 2023

Nov 14, 2023

BUY
$18.55 - $39.96 $7.93 Million - $17.1 Million
427,256 New
427,256 $16.4 Million

Others Institutions Holding IMVT

About Immunovant, Inc.


  • Ticker IMVT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 129,077,000
  • Market Cap $3.55B
  • Description
  • Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of mya...
More about IMVT
Track This Portfolio

Track Two Seas Capital LP Portfolio

Follow Two Seas Capital LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Two Seas Capital LP, based on Form 13F filings with the SEC.

News

Stay updated on Two Seas Capital LP with notifications on news.